Incannex: Positive pre-IND meeting with US FDA

Following guidance from FDA, Incannex is delighted to report that it will expand its development program to assesses the potential for IHL-675A to become a multi-use pharmaceutical drug. IHL has received positive pre-clinical results from five distinct in vivo assessments of IHL-675A applicable to various disorders caused by excessive inflammation.